Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
Luis G Paz-Ares, Alexander Valerievich Luft, Ali Tafreshi et al. · Journal of Clinical Oncology · 2018
105 Background: Pembro plus pemetrexed and carboplatin resulted in superior objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) for untreated pts with non-sq NSCLC. Pembro is active in sq NSCLC, so combining with chemo is a rational next step. Methods: KEYNOTE-407 (NCT02775435) is a randomized, placebo-controlled, global study of 560 untreated pts with metastatic sq NSCLC with ECOG 0-1. Pts were stratified by type of taxane, PD-L1 (TPS <1% vs ≥1%), and site (East Asia vs other). Investigators chose taxane. Pts were randomized 1:1 to receive carboplatin 6 mg/mL/min and paclitaxel 200 mg/m2 every 3 weeks or nab-paclitaxel 100 mg/m2 weekly plus pembro or saline placebo for 4 cycles followed by pembro/placebo for a total of 35 treatments. Imaging is sent for blinded independent central review (BICR) per RECIST 1.1. The primary endpoints are PFS by BICR and OS in the intent-to-treat population. Alpha is strictly controlled at 0.025 one-sided; PFS and OS each have 0.01. A key secondary endpoint is ORR by BICR in about the first 200 pts randomized with 0.005 alpha. A second interim analysis will be performed on PFS and OS when approximately 332 PFS events will have occurred. The hazard ratio (target 0.7) will be estimated using a stratified Cox regression model. The arms will be compared with a stratified log-rank test. Enrollment completed at the end of 2017. Results: In the first interim analysis, the initial 204 pts were randomized 101 to pembro + chemo and 103 to chemo with median follow-up of 7.7 m (range 0.4, 13.9). Pts were 78% male, 48% < 65 y, and 28% ECOG PS 0. PD-L1 status was 35% TPS<1%. 32% used nab-paclitaxel. Per BICR pembro + chemo had an ORR of 58.4% compared to 35.0%, p-value 0.0004. Duration of response ≥6m was 65.8% for pembro + chemo and 45.6% for chemo by Kaplan-Meier estimates. Incidence grade ≥3 AEs was 64.4% for pembro + chemo and 74.5% for chemo. No new safety concerns were observed. Conclusions: Adding pembro almost doubled the ORR of chemo for pts with untreated metastatic sq NSCLC. Pembro + chemo has a tolerable safety profile. Results from a second interim analysis may be available prior to the meeting. Clinical trial information: NCT02775435.
Cited by 121 works. doi:10.1200/jco.2018.36.15_suppl.105